<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5421914</article-id><article-id pub-id-type="pmid">28445989</article-id><article-id pub-id-type="publisher-id">15931</article-id><article-id pub-id-type="doi">10.18632/oncotarget.15931</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title><italic>TMPRSS2:ERG</italic> gene fusion variants induce TGF-&#x003b2; signaling and epithelial to mesenchymal transition in human prostate cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ratz</surname><given-names>Leonie</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Laible</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kacprzyk</surname><given-names>Lukasz A</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wittig-Blaich</surname><given-names>Stephanie M</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tolstov</surname><given-names>Yanis</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duensing</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Altevogt</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Klauck</surname><given-names>Sabine M</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>S&#x000fc;ltmann</surname><given-names>Holger</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Cancer Genome Research Group, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany</aff><aff id="A2"><sup>2</sup> Department of Urology, Section of Molecular Urooncology, University Hospital Heidelberg, 69120 Heidelberg, Germany</aff><aff id="A3"><sup>3</sup> Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany</aff><aff id="A4"><sup>4</sup> Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, 68135 Mannheim, Germany</aff><aff id="A5"><sup>5</sup> Present address: BioNTech Diagnostics GmbH, 55131 Mainz, Germany</aff><aff id="A6"><sup>6</sup> Present address: UGA Biopharma GmbH, 16761 Hennigsdorf, Germany</aff><aff id="A7"><sup>7</sup> Present address: Institute of Comparative Molecular Endocrinology (CME), University of Ulm, 89081 Ulm, Germany</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Holger S&#x000fc;ltmann, <email>h.sueltmann@dkfz.de</email></corresp></author-notes><pub-date pub-type="collection"><day>11</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>6</day><month>3</month><year>2017</year></pub-date><volume>8</volume><issue>15</issue><fpage>25115</fpage><lpage>25130</lpage><history><date date-type="received"><day>25</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Ratz et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p><italic>TMPRSS2:ERG</italic> (T/E) gene fusions are present in approximately 50% of all prostate cancer (PCa) cases. The expression of fusion mRNAs from distinct T/E variants is associated with clinicopathological parameters, while the underlying molecular processes remain unclear. We characterized the molecular mechanisms and functional implications caused by doxycycline (Dox)-inducible overexpression of the frequent T/E III and VI fusion variants in LNCaP cells. Induction of T/E expression resulted in increased cellular migratory and invasive potential, and reduced proliferation and accumulation in G1 phase. T/E overexpressing cells showed epithelial-to-mesenchymal transition (EMT), as demonstrated by upregulation of TGF-&#x003b2; and WNT pathway genes, mesenchymal markers, and increased phosphorylation of the p38 MAPK. Augmented secretion of TGF-&#x003b2;1 and &#x02013;&#x003b2;2, and T/E-mediated regulation of ALK1, a member of the TGF-&#x003b2; receptor family, was detected. <italic>ALK1</italic> inhibition in T/E overexpressing cells blocked p38 phosphorylation and reduced the expression of the TGF-&#x003b2; target genes <italic>VIM</italic>, <italic>MMP1</italic>, <italic>CDH2</italic>, and <italic>SNAI2</italic>. We found a T/E variant VI-specific induction of <italic>miR-503</italic> associated with reduced expression of SMAD7 and CDH1. Overexpression of <italic>miR-503</italic> led to increased levels of <italic>VIM</italic> and <italic>MMP1</italic>. Our findings indicate that TGF-&#x003b2; signaling is a major determinant of EMT in T/E overexpressing LNCaP cells. We provide evidence that T/E VI-specific transcriptional modulation by miR-503 accounts for differences in the activation of EMT pathway genes, promoting the aggressive phenotype of tumors expressing T/E variant VI. We suggest that ALK1-mediated TGF-&#x003b2; signaling is a novel oncogenic mechanism in T/E positive PCa.</p></abstract><kwd-group><kwd>TMPRSS2:ERG fusion variants</kwd><kwd>TGF-&#x003b2; signaling</kwd><kwd>ALK1</kwd><kwd>EMT</kwd><kwd>prostate cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Prostate cancer (PCa) is the most frequently diagnosed cancer among men in Western countries and a major cause of cancer-related mortality [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. PCa is a heterogeneous disease with several molecular and clinicopathological subtypes. The <italic>TMPRSS2:ERG</italic> (T/E) gene fusion, resulting from a chromosomal rearrangement of <italic>ERG</italic> (v-ets erythroblastosis virus E26 homolog (avian)) to the androgen responsive gene <italic>TMPRSS2</italic> (transmembrane protease, serine 2), is the most frequent somatic alteration in PCa [<xref rid="R3" ref-type="bibr">3</xref>], and detectable in 50% of the tumors [<xref rid="R4" ref-type="bibr">4</xref>]. In those cases, <italic>ERG</italic> overexpression is driven by the androgen-responsive promoter of <italic>TMPRSS2</italic>, resulting in upregulation of ERG protein and activation of downstream target genes [<xref rid="R5" ref-type="bibr">5</xref>]. Ninety percent of PCas overexpressing ERG harbor T/E fusions [<xref rid="R5" ref-type="bibr">5</xref>]. However, no consensus on the prognostic significance of T/E fusion-positive tumors has been reached so far [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>]. This may be due to differences in tumor characteristics and multiple T/E isoforms [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>], which have been associated with clinicopathological parameters [<xref rid="R10" ref-type="bibr">10</xref>] and progression [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. The most common fusion mRNA variant III (T/E III), containing exon 1 of <italic>TMPRSS2</italic> (1-17bp) and exons 4-11 of <italic>ERG</italic> (T1/E4), is present in 86% of fusion-positive tumors [<xref rid="R10" ref-type="bibr">10</xref>]. Since exon 1 of <italic>TMPRSS2</italic> is noncoding, this mRNA is translated from an internal ATG site, resulting in a truncated ERG protein. The expression of T/E VI, resulting from fusion of exons 1-2 of <italic>TMPRSS2</italic> to exons 4-11 of <italic>ERG</italic> (T2/E4), has been associated with aggressive disease [<xref rid="R10" ref-type="bibr">10</xref>]. This mRNA is translated from a start codon within <italic>TMPRSS2</italic> exon 2 that is in frame with the <italic>ERG</italic> ORF. The resulting protein includes the first five amino acids of TMPRSS2 and lacks the first 12 amino acids of the full-length ERG protein.</p><p>Previously, we found T/E specific transcriptional upregulation of genes associated with activated TGF-&#x003b2;/BMP and WNT signaling in fusion-positive PCa compared to fusion-negative PCa [<xref rid="R13" ref-type="bibr">13</xref>]. TGF-&#x003b2; and WNT signaling regulate a diverse range of cellular processes related to cancer progression [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>] and are major inducers of epithelial-to-mesenchymal transition (EMT) [<xref rid="R16" ref-type="bibr">16</xref>]. Here, our aim was to characterize the molecular mechanisms and functional implications of T/E variant overexpression and their consequences on cellular and molecular phenotypes. We focused on the analysis of T/E III and T/E VI gene fusion variants based on their frequencies of occurrence and their association with clinical and pathological variables. We established LNCaP cells, featuring androgen-independency with high levels of androgen receptor (AR), stably overexpressing the T/E III and VI variants in an inducible promoter system (LNCaP-T/E) and examined the effects of overexpression on cellular properties and signal transduction pathways. To validate the observed transcriptional modulation upon ERG overexpression in LNCaP, the T/E-positive prostate cancer cell line NCI-H660 [<xref rid="R17" ref-type="bibr">17</xref>] was employed. This cell line harbors both T/E III and T/E VI fusions [<xref rid="R17" ref-type="bibr">17</xref>]. Complementary to the LNCaP-T/E model, ERG was silenced in NCI-H660 using an ERG-specific siRNA and mRNA levels of the targets previously measured in LNCaP-T/E clones were assessed. Overall, we found a large degree of commonality but also distinct transcriptional effects between T/E III and VI variants.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Characterization of T/E expressing LNCaP cells</title><p>To study the role of the T/E gene fusion variants (Figure <xref ref-type="fig" rid="F1">1A</xref>), we made use of a Flp recombinase based transfection system allowing stable and inducible expression of T/E variants III and VI in LNCaP cells. An empty expression vector served as a control. The expression of T/E variants was verified using RT-PCR (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1B</xref>). QPCR analysis after Dox-induction showed &#x0223c;50-fold and &#x0223c;150-fold upregulation of <italic>ERG</italic> in T/E III and T/E VI cells, respectively (Figure <xref ref-type="fig" rid="F1">1B</xref>). Western blot analysis confirmed the expression of ERG protein in Dox-induced LNCaP-T/E cells only (Figure <xref ref-type="fig" rid="F1">1C</xref>). In line with previous reports that ERG expression leads to downregulation of <italic>AR</italic> transcripts [<xref rid="R18" ref-type="bibr">18</xref>], both LNCaP-T/E III and VI cell lines showed markedly decreased AR protein after ERG overexpression (Figure <xref ref-type="fig" rid="F1">1C</xref>), indicating that the cell lines faithfully reflect the <italic>in vivo</italic> situation. Concurrent with reports that lower AR expression is associated with reduced differentiation of PCa cells [<xref rid="R19" ref-type="bibr">19</xref>], we noticed morphological changes, including cellular rounding, spindle-like branching, and detachment from adjacent cells (Figure <xref ref-type="fig" rid="F1">1D</xref>), which resembled a fibroblast-like morphology. These results suggested that ERG affects processes controlling the morphology of LNCaP cells.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>S/E variant overexpression in LNCaP cells</title><p><bold>(A)</bold> Structure of T/E gene fusion variants III and VI; <italic>TMPRSS2</italic> (RefSeq NM_005656), <italic>ERG</italic> (RefSeq NM_004449.4). Downward pointing arrowheads: position of <italic>ERG</italic> fusion break point in T/E III (white) and T/E VI (black). Upward black pointing arrowhead: translation initiation codon. Protein domains: PNT, pointed domain (a protein&#x02013;protein interaction site); NID, N-terminal inhibitory domain; Ets, Ets-DNA binding domain; CAD, C-terminal activator domain. <bold>(B)</bold> qPCR of Dox-induced <italic>ERG</italic> expression in T/E III and T/E VI compared to uninduced cells. &#x00394;C <italic>p</italic> values from three independent experiments are shown relative to <italic>GAPDH</italic>. <bold>(C)</bold> Western blot analysis of ERG and AR expression in empty vector (Ev), T/E III and T/E VI LNCaP cells, respectively. GAPDH served as protein loading control. <bold>(D)</bold> Morphological changes induced by Dox-mediated ERG overexpression in T/E III and T/E VI and control LNCaP cells. Pictures were taken at 20-fold magnification after 72h Dox induction. <bold>(E)</bold> Cell growth was measured by a WST-1 assay at the indicated time points after pre-treatment with Dox (three independent experiments). <bold>(F)</bold> Cell cycle analysis using flow cytometry with propidium iodide (PI) staining. T/E III, T/E VI and empty vector cells were either not treated (&#x02212;) or treated with Dox (+) and analyzed 72h post induction. Data are shown as percent positive staining cells &#x000b1; s.d. of three independent experiments. <bold>(G&#x02013;H)</bold> Quantification of (G) migrated, and (H) invaded T/E expressing cells with a transwell chamber assay. Eight microscopic fields per treatment were analyzed and results of three independent experiments are shown. Ev &#x02013; Empty vector; ns &#x02013; not significant.</p></caption><graphic xlink:href="oncotarget-08-25115-g001"/></fig></sec><sec id="s2_2"><title>T/E overexpression confers oncogenic properties to LNCaP cells</title><p>The impact of T/E overexpression on LNCaP cells was analyzed using proliferation, migration and invasion assays. T/E overexpressing cells showed reduced proliferation from 48 h to 96 h post induction (Figure <xref ref-type="fig" rid="F1">1E</xref>). After 72 h, a decreased number of cells in S- and G2-phase while an increased number in G1-phase was observed (Figure <xref ref-type="fig" rid="F1">1F</xref>) for both T/E III and VI variants. No apoptotic cells were detectable in the sub-G1 fractions. Thus, T/E overexpression induced cell cycle changes leading to the accumulation of cells in G1 phase and reduced cell proliferation without apoptosis. T/E expressing LNCaP cells migrated and invaded significantly faster compared to uninduced or empty vector controls (Figure <xref ref-type="fig" rid="F1">1G</xref> and <xref ref-type="fig" rid="F1">1H</xref>) and the migration rate was higher in T/E VI compared to T/E III cells (Figure <xref ref-type="fig" rid="F1">1G</xref>).</p></sec><sec id="s2_3"><title>Overexpression of T/E III and VI variants reveal transcriptional programs associated with TGF-&#x003b2; signaling</title><p>The transcriptional programs regulated by T/E overexpression were investigated by microarray expression profiling on 48,107 genes (GEO accession GSE78032). Differentially expressed genes (&#x0003e; 1.5 fold change cut-off; <italic>p</italic> &#x0003c; 0.05) compared to empty vector control (<italic>n</italic> = 4,429; <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>) were selected for further analysis using the Ingenuity Pathway Analysis (IPA) program. Of the 2,205 genes, which were altered in both T/E III and VI variants (<italic>T/E intersection</italic>; <xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>), 94% showed concordant expression changes, indicating a high degree of accordance between the variants. The number of distinct genes found after T/E III or VI overexpression (<italic>T/E III only</italic> and <italic>T/E VI only</italic>) was 418 and 1,806, respectively (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>).</p><p>Comparison of differential mRNA expression between LNCaP-T/E cells and T/E-positive <italic>ex vivo</italic> tumors [<xref rid="R13" ref-type="bibr">13</xref>] revealed 30% (37/126) overlap, including the genes Tudor Domain Containing 1 <italic>(TDRD1</italic>), Cluster of Differentiation 24 (<italic>CD24</italic>), BMP And Activin Membrane-Bound Inhibitor (<italic>BAMBI</italic>), and Cyclin-Dependent Kinase 1 (<italic>CDK1</italic>) [<xref rid="R13" ref-type="bibr">13</xref>]. Furthermore, transcriptional changes in T/E overexpressing cells were consistent with the expected transcriptional response to ERG overexpression based on previous findings. For example, <italic>AR</italic> and the androgen-responsive genes <italic>TMPRSS2</italic> [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R18" ref-type="bibr">18</xref>], <italic>SLC45A3</italic> [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>], <italic>ACPP</italic> [<xref rid="R19" ref-type="bibr">19</xref>], and <italic>MSMB</italic> [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R19" ref-type="bibr">19</xref>] were downregulated, whereas genes known to be activated by ERG, e.g. <italic>PLAT</italic> [<xref rid="R18" ref-type="bibr">18</xref>], <italic>PLA1A</italic> [<xref rid="R5" ref-type="bibr">5</xref>], and <italic>MMP1</italic> [<xref rid="R20" ref-type="bibr">20</xref>] were upregulated. These data indicated that our T/E expressing cell models faithfully reflected the transcriptional regulation in T/E-positive tumors and are suio study the biology of the variants.</p><p>GO analysis in IPA using the <italic>T/E intersection</italic> (<italic>n</italic> = 2,205) showed that genes associated with cell proliferation and interphase were downregulated (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>), which was in agreement with the reduced proliferative ability of LNCaP-T/E cells (Figure <xref ref-type="fig" rid="F1">1E</xref>). &#x02018;Estrogen-mediated S-phase Entry&#x02019; was identified among the top significantly enriched canonical pathways (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>). This corresponded to the accumulation of the T/E overexpressing cells in G1 phase (Figure <xref ref-type="fig" rid="F1">1F</xref>). Consistent with the increased number of migrated and invaded cells found in the transwell assays (Figure <xref ref-type="fig" rid="F1">1G</xref> and <xref ref-type="fig" rid="F1">1H</xref>), genes belonging to the category &#x02018;Cell invasion&#x02019; were primarily upregulated (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p><p>To study potential mechanisms regulating transcriptional changes associated with increased migration and invasion in LNCaP-T/E cells, an upstream regulator analysis was performed with the <italic>T/E intersection</italic> dataset (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>). This analysis revealed transforming growth factor beta 1 (<italic>TGFB1</italic>) as an upstream regulator of 284 genes that were directly associated with <italic>TGFB1</italic> regulation (<xref rid="SD3" ref-type="supplementary-material">Supplementary Table 4</xref>), and indicated that TGF-&#x003b2; signaling plays a crucial role in T/E overexpressing cells as previously suggested by us [<xref rid="R13" ref-type="bibr">13</xref>]. Evidence for activated TGF-&#x003b2; signaling in the differentially expressed gene set (<italic>n</italic> = 4,429) was provided by upregulation of several TGF-&#x003b2; pathway-specific genes, e.g. bone morphogenetic protein 1 (<italic>BMP1</italic>), or downregulation of negative regulators of TGF-&#x003b2; signaling, such as the pseudoreceptor <italic>BAMBI</italic> (Figure <xref ref-type="fig" rid="F2">2A</xref>). Activation of noncanonical TGF-&#x003b2; signaling was evident by upregulation of SMAD-independent molecules involved in the ERK, JNK/p38 and PI3K/AKT pathways (Figure <xref ref-type="fig" rid="F2">2A</xref>). We also found upregulation of EMT-inducing transcription factors (<italic>SNAI2</italic>, <italic>ZEB1</italic>), mesenchymal markers (<italic>FN1</italic>, <italic>VIM</italic>, <italic>VTN</italic>) and matrix metalloproteinases (<italic>MMP1</italic>, <italic>MMP10</italic>), and downregulation of E-cadherin (<italic>CDH1</italic>) (Figure <xref ref-type="fig" rid="F2">2A</xref>), again supporting our finding that T/E expressing cells lose epithelial characteristics and acquire a mesenchymal phenotype. Of note, the upregulated genes included the type I TGF-&#x003b2; receptor Activin A Receptor Like Type 1 (<italic>ACVRL1</italic>, also known as <italic>ALK1</italic>) (Figure <xref ref-type="fig" rid="F2">2A</xref>), as well as the WNT receptor Frizzled 4 (<italic>FZD4</italic>) and its co-receptors <italic>LRP5</italic> and <italic>LRP6</italic> (Figure <xref ref-type="fig" rid="F2">2A</xref>), suggesting that these receptors might be mediators of transcriptional changes leading to EMT in T/E overexpressing cells.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Transcriptional modulation in LNCaP-T/E cells</title><p><bold>(A)</bold> Microarray gene expression data indicating activated TGF-&#x003b2; and EMT-inducing signaling pathways in T/E expressing cells. <bold>(B&#x02013;C)</bold> qPCR validation of T/E-induced gene expression changes associated with an EMT profile. (B) mRNA expression after T/E induction relative to uninduced controls. (C) mRNA levels of selected targets showing prominent transcriptional modulation in T/E III and VI overexpressing cells. Data are shown as &#x00394;C <italic>p</italic> values relative to <italic>GAPDH</italic> measured in the same samples, which had been used for the microarray analysis. Ev - Empty vector; NS/ns - not significant. Red - upregulated; blue - downregulated.</p></caption><graphic xlink:href="oncotarget-08-25115-g002"/></fig><p>Validation of the microarray data by qPCR verified the strong upregulation of <italic>ALK1</italic> and <italic>FZD4</italic> in both LNCaP-T/E variants (Figure <xref ref-type="fig" rid="F2">2B</xref>) as well as upregulation of EMT-inducing components and downregulation of genes negatively associated with TGF-&#x003b2; signaling (Figure <xref ref-type="fig" rid="F2">2B</xref>). Notably, the validation confirmed the strong upregulation of the selected EMT inducing ligands (<italic>TGFB1</italic>, 7.3-fold; <italic>TGFB2</italic>, 5.5-fold) and downstream effector genes (<italic>TCF7L2</italic>, 5.1-fold; <italic>SNAI2</italic>, 4.7-fold) in T/E VI cells, whereas <italic>CDH1</italic> (4.3-fold) and <italic>SMAD7</italic> (2.3-fold) were downregulated in T/E VI compared to T/E III expressing cells (Figure <xref ref-type="fig" rid="F2">2C</xref>).</p></sec><sec id="s2_4"><title>Distinct intracellular signaling molecules are regulated in T/E variants</title><p>TGF-&#x003b2; signaling is mediated by SMAD-dependent and -independent signaling pathways involving JNK/p38 MAPK and PI3K/AKT [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>]. Multiplex protein quantification using Luminex technology and Western blot (Figure <xref ref-type="fig" rid="F3">3</xref>) for TGF-&#x003b2; signaling analysis revealed increased phosphorylation of p38 MAPK (Figure <xref ref-type="fig" rid="F3">3A</xref> and <xref ref-type="fig" rid="F3">3B</xref>), AKT (T/E III cells only; Figure <xref ref-type="fig" rid="F3">3C, 3D</xref> and <xref ref-type="fig" rid="F3">3E</xref>), JNK (Figure <xref ref-type="fig" rid="F3">3F</xref>), and SMAD1/5 (Figure <xref ref-type="fig" rid="F3">3G</xref>) upon T/E overexpression. Increased levels of p-SMAD1/5 and p-p38 were detectable 4h after T/E induction, concomitant with increasing ERG levels in T/E III and T/E VI cells. Increased phosphorylation of SMAD2 and 3 was not observed (data not shown). The increased AKT phosphorylation in T/E III, but not in T/E VI, expressing cells (Figure <xref ref-type="fig" rid="F3">3C, 3D</xref> and <xref ref-type="fig" rid="F3">3E</xref>) went along with the increasing ERG expression as confirmed by quantitative analysis showing the pAKT/AKT ratio in induced and uninduced cells, albeit this was not significant (Figure <xref ref-type="fig" rid="F3">3E</xref>). High basal levels of pAKT were observed in T/E III cells (Figure <xref ref-type="fig" rid="F3">3D</xref>). Activation of survival-associated processes corresponded to the functional annotation of the T/E gene set (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>). TGF-&#x003b2;-mediated AKT activation has previously been proposed to overcome the growth-inhibitory effects of TGF-&#x003b2; in BPH1 tumorigenic sublines [<xref rid="R23" ref-type="bibr">23</xref>]. Taken together, these findings provided evidence for increased TGF-&#x003b2; signaling in both T/E variants, as well as an activated AKT dependent survival network upon T/E III overexpression, that might act together to induce EMT in this PCa cell model.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Signaling pathways in T/E expressing cells</title><p>Activation of signaling molecules (p38, AKT, JNK, and SMAD1/5) in T/E expressing cells measured by Luminex technology <bold>(A, C, F)</bold>, and Western blot analysis <bold>(B, D, G)</bold>. For Western blot analysis, GAPDH served as loading control. Increased p38 phosphorylation (Thr180/Tyr182) was evident in T/E III (B) and T/E VI (A, B) cells. T/E III cells showed increased AKT phosphorylation (Ser473) (C, D). <bold>(E)</bold> pAKT/AKT ratios after densitometric analysis of Western blot bands of (D). (F) Increased JNK phosphorylation (Thr183/Tyr185) was revealed in T/E VI cells. Increased pSMAD1/5 phosphorylation (Ser463/465) was evident in (G) T/E III cells.</p></caption><graphic xlink:href="oncotarget-08-25115-g003"/></fig></sec><sec id="s2_5"><title>Soluble TGF-&#x003b2; is produced by T/E overexpressing cells</title><p>Increased <italic>TGFB1</italic> and <italic>-2</italic> levels in T/E overexpressing cells motivated us to test whether TGF-&#x003b2; is secreted to act in an autocrine manner. Active TGF-&#x003b2; was measured in cell-free conditioned medium using Luminex immunoassays 72 h after Dox induction. T/E III and VI overexpressing cells displayed considerably increased TGF-&#x003b2;1 (7-fold and 2-fold, respectively) and TGF-&#x003b2;2 (6-fold and 3-fold, respectively) protein compared to controls (Figure <xref ref-type="fig" rid="F4">4A</xref>). Thus, T/E overexpression induced secretion of TGF-&#x003b2;1 and TGF-&#x003b2;2. SiRNA-mediated <italic>ERG</italic> knockdown in the NCI-H660 PCa cell line carrying both T/E fusion variants III and VI [<xref rid="R17" ref-type="bibr">17</xref>] reduced <italic>TGFB1</italic> mRNA levels (Figure <xref ref-type="fig" rid="F5">5A</xref>), further supporting the T/E-mediated upregulation of TGF-&#x003b2; ligands. Moreover, siRNA-mediated <italic>TGFB1</italic> knockdown in T/E III and VI cells led to upregulation of the negative TGF-&#x003b2; regulators <italic>BAMBI</italic> (in T/E III and VI cells) and <italic>SMAD7</italic> (only in T/E VI cells, Figure <xref ref-type="fig" rid="F4">4B</xref> and <xref ref-type="fig" rid="F4">4C</xref>), indicating that <italic>TGFB1</italic> plays a role in T/E-induced TGF-&#x003b2; signaling.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>TGF-&#x003b2; signaling in LNCaP-T/E cells</title><p><bold>(A)</bold> TGF-&#x003b2;1 and TGF-&#x003b2;2 released into the medium was determined in cell-free conditioned medium derived from Dox-induced (+) and uninduced (&#x02212;) LNCaP-T/E cells, respectively. All Luminex results are presented as MFI (mean fluorescent intensity) values &#x000b1; s.d. of three independent experiments. Ev - Empty vector. <bold>(B&#x02013;C)</bold> siRNA-mediated knockdown of <italic>TGFB1</italic> using 20 nM siRNA show upregulation of <italic>BAMBI</italic> in (B) T/E III and (C) T/E VI cells and additionally <italic>SMAD7</italic> in T/E VI cells (C) as determined by qPCR.</p></caption><graphic xlink:href="oncotarget-08-25115-g004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>ALK1 inhibitors decrease T/E-induced ALK1 signaling</title><p><bold>(A)</bold>
<italic>ERG</italic> knockdown in NCI-H660 cells (50 nM) showed reduced levels of <italic>TGFB1</italic> and <italic>ALK1</italic>. <bold>(B)</bold> Western blot analysis in LNCaP-T/E cells revealed reduced p38 phosphorylation after treatment with rhALK1 (5&#x003bc;g/mL) compared to PBS-treated control cells. <bold>(C)</bold> p-p38/p38 ratios after densitometric analysis of Western blot bands shown in (B) in T/E III and T/E VI cells, respectively. <bold>(D&#x02013;E)</bold> Expression levels of TGF-&#x003b2;-responsive genes in (D) T/E III and (E) T/E VI expressing cells after rhALK1 treatment (5&#x003bc;g/mL) determined by qPCR. <bold>(F)</bold> Western blot analysis of p38 phosphorylation after treatment with K02288 (at indicated concentrations) compared to DMSO-treated control cells. <bold>(G)</bold> p-p38/p38 ratios after densitometric analysis of Western blot bands shown in (F) of T/E III and T/E VI cells, respectively. <bold>(H&#x02013;I)</bold> Expression levels of TGF-&#x003b2;/BMP-responsive genes in (H) T/E III and (I) T/E VI expressing cells after simultaneous treatment with Dox and K02288 (500nM) were determined by qPCR.</p></caption><graphic xlink:href="oncotarget-08-25115-g005"/></fig></sec><sec id="s2_6"><title>ALK1 signaling regulates p38 MAPK and EMT markers</title><p>Since <italic>ALK1</italic> mRNA was strongly upregulated in T/E overexpressing cells (40-fold in T/E III and 500-fold in T/E VI cells; Figure <xref ref-type="fig" rid="F2">2B</xref>), we analyzed this pathway in more detail. <italic>ERG</italic> knockdown in NCI-H660 cells led to reduced <italic>ALK1</italic> mRNA levels (Figure <xref ref-type="fig" rid="F5">5A</xref>) confirming the association between ERG and ALK1 expression. Next, Dox-induced LNCaP-T/E cells were incubated with a human recombinant decoy receptor (rhALK1) [<xref rid="R24" ref-type="bibr">24</xref>] or the ALK1 inhibitor K02288 [<xref rid="R25" ref-type="bibr">25</xref>]. Disruption of ALK1 signaling using rhALK1 (Figure <xref ref-type="fig" rid="F5">5B</xref> and <xref ref-type="fig" rid="F5">5C</xref>) or K02288 (Figure <xref ref-type="fig" rid="F5">5F</xref> and <xref ref-type="fig" rid="F5">5G</xref>) resulted in reduced p38 phosphorylation. As expected [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>], the inhibitor of differentiation 1 (<italic>ID1</italic>), and <italic>ID2</italic> genes were upregulated after ERG induction, but reduced after rhALK1 (Figure <xref ref-type="fig" rid="F5">5D</xref> and <xref ref-type="fig" rid="F5">5E</xref>) or K02288 (Figure <xref ref-type="fig" rid="F5">5H</xref> and <xref ref-type="fig" rid="F5">5I</xref>) treatment. These data suggested that T/E overexpression induces ALK1-signaling and supported the concept that ALK1-mediated phosphorylation of p38 confers mesenchymal transformation of PCa cells. In line with this, rhALK1-mediated inhibition of ALK1 signaling led to reduced expression of <italic>MMP1</italic> (52% reduction) in T/E III (Figure <xref ref-type="fig" rid="F5">5D</xref>), and <italic>MMP1</italic>, <italic>VIM</italic>, and <italic>SNAI2</italic> (39%, 22%, and 5% reduction, respectively) in T/E VI cells (Figure <xref ref-type="fig" rid="F5">5E</xref>). ALK1 inhibition by K02288 also resulted in reduced expression of <italic>MMP1</italic> and <italic>CDH2</italic> (35% and 61% reduction, respectively) in T/E III (Figure <xref ref-type="fig" rid="F5">5H</xref>) and <italic>MMP1</italic>, <italic>CDH2</italic>, <italic>VIM</italic>, and <italic>SNAI2</italic> (72%, 50%, 40%, and 48% reduction, respectively) in T/E VI overexpressing cells (Figure <xref ref-type="fig" rid="F5">5I</xref>).</p></sec><sec id="s2_7"><title>T/E overexpression activates &#x003b2;-catenin signaling in prostate cancer cells</title><p>WNT/&#x003b2;-catenin and TGF-&#x003b2; signaling pathways share key molecules (p38 MAPK, SNAI1/2, ZEB1/2 [<xref rid="R16" ref-type="bibr">16</xref>]) and can synergistically induce changes associated with EMT. Since we had identified an EMT transcriptional signature and upregulation of the WNT/&#x003b2;-catenin target genes in T/E overexpressing cells (Figure <xref ref-type="fig" rid="F2">2A&#x02013;2C</xref>), we characterized signaling downstream of WNT in more detail. Overexpression of both T/E variants led to increased &#x003b2;-catenin signaling (Figure <xref ref-type="fig" rid="F6">6A</xref>), which was 2.4-fold higher in T/E VI compared to T/E III overexpressing cells. To test whether induction of gene expression was mediated by FZD4 upregulation, we incubated cells with rhFZD4. Disruption of FZD4-signaling showed a clear reduction of p38 phosphorylation in T/E III and T/E VI cells by Western blot (Figure <xref ref-type="fig" rid="F6">6B</xref>), and band quantification (Figure <xref ref-type="fig" rid="F6">6C</xref>). Further, we observed reduced <italic>MMP1</italic>, <italic>VIM</italic>, and <italic>CDH2</italic> levels in T/E III and VI (Figure <xref ref-type="fig" rid="F6">6D</xref> and <xref ref-type="fig" rid="F6">6E</xref>) and additionally reduced <italic>SNAI2</italic> in T/E VI cells (Figure <xref ref-type="fig" rid="F6">6E</xref>). These data suggest that FZD4-induced oncogenic effects of T/E overexpression are mediated by p38.</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>T/E expression induces FZD4-mediated &#x003b2;-catenin signaling in LNCaP cells</title><p><bold>(A)</bold> TOPflash luciferase activity 72 h post induction. Mean &#x000b1; s.d. of three independent experiments are shown. TOPflash activity was normalized to mutant FOPflash activity and relative to uninduced clones. (<bold>B</bold>&#x02013;<bold>E</bold>) Effects of FZD4-specific inhibition using rhFZD4 for 48h compared to PBS-treated control cells. (B) Phosphorylation of p38 was measured by Western blotting and p-p38/p38 (C) ratio was determined after band analysis of (B). (D&#x02013;E) EMT target gene expression after rhFZD4 treatment (5&#x003bc;g/ml) was assessed by qPCR in T/E III (D) and T/E VI (E) cells. Ev - Empty vector.</p></caption><graphic xlink:href="oncotarget-08-25115-g006"/></fig></sec><sec id="s2_8"><title>Upregulation of <italic>miR-503</italic> in T/E VI cells promotes EMT by targeting <italic>SMAD7</italic></title><p>We further aimed to identify determinants of the stronger activation of EMT regulating pathways genes in T/E VI expressing cells. We focused on <italic>miR-503</italic>, which was strongly upregulated in the <italic>T/E VI only</italic> (&#x0223c;7-fold), but not in the <italic>T/E III only</italic> microarray dataset (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>). A search for potential <italic>miR-503</italic> targets using <italic>in silico</italic> prediction algorithms showed that <italic>miR-503</italic> could target <italic>SMAD7</italic> [<xref rid="R28" ref-type="bibr">28</xref>], which was downregulated in T/E VI, but upregulated in T/E III cells. We therefore hypothesized that <italic>miR-503</italic> might be a candidate modulating the biological activity of the T/E VI fusion variants. To test whether <italic>miR-503</italic> could augment EMT, we transiently overexpressed and inhibited <italic>miR-503</italic> in T/E III and T/E VI cells using <italic>miR-503</italic> mimics and inhibitors, respectively. Only induced T/E VI cells displayed significant upregulation of <italic>miR-503</italic>, which was further increased by simultaneous <italic>miR-503</italic> overexpression (Figure <xref ref-type="fig" rid="F7">7A</xref>). Key EMT markers like <italic>VIM</italic> and <italic>MMP1</italic> were upregulated in T/E-induced cells and were further increased after <italic>miR-503</italic> overexpression (Figure <xref ref-type="fig" rid="F7">7B</xref>). Inhibition of <italic>miR-503</italic> upon induction of T/E VI expression led to a reduction of <italic>VIM</italic> (Figure <xref ref-type="fig" rid="F7">7B</xref>). The impacts of <italic>miR-503</italic> overexpression and inhibition on SMAD7, and CDH1 quantities as surrogate for a mesenchymal phenotype were examined by Western blot analysis. <italic>MiR-503</italic> overexpression led to decreased SMAD7 and CDH1 expression in T/E VI cells (Figure <xref ref-type="fig" rid="F7">7C</xref> and <xref ref-type="fig" rid="F7">7D</xref>). These results suggested that T/E VI-mediated overexpression of <italic>miR-503</italic> plays an important role in increasing EMT effectors and that <italic>miR-503</italic> can induce invasion of T/E VI expressing cells due to its ability to downregulate <italic>CDH1</italic>. Furthermore, <italic>TGFB1</italic> knockdown in T/E VI cells showed reduced expression of <italic>miR-503</italic> (Figure <xref ref-type="fig" rid="F7">7E</xref>), suggesting that the expression of <italic>miR-503</italic> is regulated by TGF-&#x003b2;, thereby contributing to enhanced TGF-&#x003b2; signaling by inhibition of <italic>SMAD7</italic> [<xref rid="R29" ref-type="bibr">29</xref>]. The varying SMAD7 levels are consistent with the observed differences in TGF-&#x003b2; and WNT/&#x003b2;-catenin signaling activity between T/E III and T/E VI cells.</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title><italic>MiR-503</italic> overexpression in T/E VI cells inhibits SMAD7 and CDH1</title><p><bold>(A)</bold> qPCR analysis of <italic>miR-503</italic> expression relative to <italic>RNU6B</italic>. Values are presented as mean &#x000b1; s.d. of three independent experiments. <bold>(B)</bold> qPCR determination of <italic>VIM</italic> and <italic>MMP1</italic> expression in T/E VI expressing cells relative to <italic>GAPDH</italic>. <bold>(C)</bold> Western blot analysis of SMAD7 and CDH1 protein expression in T/E cells. Representative results of three independent Western blot experiments are shown. <bold>(D)</bold> Quantitative analysis of protein expression relative to GAPDH is presented as mean &#x000b1; s.d. of three independent experiments. <bold>(E)</bold>
<italic>miR-503</italic> expression upon siRNA-mediated knockdown of <italic>TGFB1</italic> (20 nM) in T/E VI cells was determined by qPCR. Mimic - hsa-<italic>miR-503-5p</italic> mimic (used at 10 nM), inh - hsa-<italic>miR-503-5p</italic> inhibitor (used at 100 nM).</p></caption><graphic xlink:href="oncotarget-08-25115-g007"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>Previously, we reported that transcriptional changes in T/E positive tumors are associated with deregulated TGF-&#x003b2;/BMP and WNT signaling pathways [<xref rid="R13" ref-type="bibr">13</xref>]. Here, by deploying inducible T/E overexpression in LNCaP cell models, we show that overexpression of two distinct T/E variants induce common as well as unique signaling programs that are able to lead the cells into EMT. Upon T/E overexpression, the cells acquire mesenchymal, fibroblast-like morphologies [<xref rid="R30" ref-type="bibr">30</xref>]. On the molecular level, this is accompanied by downregulation of AR, suggesting that ERG disrupts a lineage-specific differentiation program of prostate cells [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>], and upregulation of EMT effector genes, like <italic>MMP1</italic> and <italic>VIM</italic>, which are correlated with poor PCa tissue differentiation [<xref rid="R31" ref-type="bibr">31</xref>] and metastasis formation [<xref rid="R32" ref-type="bibr">32</xref>]. Furthermore, upregulated EMT-associated genes included the transcription factors <italic>ZEB1</italic> [<xref rid="R30" ref-type="bibr">30</xref>] and <italic>TCF/LEF-1</italic> [<xref rid="R33" ref-type="bibr">33</xref>], as well as <italic>TGFB1</italic> and <italic>-2</italic> [<xref rid="R34" ref-type="bibr">34</xref>]. We also show that T/E overexpression significantly enhances the invasion capability of LNCaP cells. These results are in agreement with the role of T/E overexpression in promoting cell invasion via induction of matrix metalloproteinase and plasminogen activator genes [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. Global gene expression analysis of T/E overexpressing cells led to significantly overrepresented GO categories (proliferation and invasion), which correlated with the observed cellular phenotype. We further found many components of known signaling pathways, including JNK/p38 MAPKs, AKT and SMAD1/5, to be deregulated (Figure <xref ref-type="fig" rid="F8">8</xref>). Importantly, <italic>TGFB1</italic> was identified as a regulator gene of T/E-induced transcriptional changes, which again supports our previous <italic>ex vivo</italic> data [<xref rid="R13" ref-type="bibr">13</xref>]. Increased TGF-&#x003b2; expression has been shown to induce a tumor-promoting phenotype [<xref rid="R35" ref-type="bibr">35</xref>] facilitating metastatic dissemination [<xref rid="R36" ref-type="bibr">36</xref>]. TGF-&#x003b2;/BMP signaling is well known for its role in bone remodeling and metastasis formation in breast cancer [<xref rid="R35" ref-type="bibr">35</xref>] and could therefore play a role in promoting PCa metastases. Bone metastasis is a common site of PCa dissemination [<xref rid="R37" ref-type="bibr">37</xref>], and expression of TGF-&#x003b2; in PCa is correlated to metastasis and survival [<xref rid="R38" ref-type="bibr">38</xref>]. Intriguingly, serum TGF-&#x003b2; concentrations are elevated in PCa patients with bone metastases [<xref rid="R39" ref-type="bibr">39</xref>]. Furthermore, TGF-&#x003b2; protein and RNA expression was higher in bone metastases compared to visceral metastases in rapid autopsy specimens of patients who died of metastatic PCa [<xref rid="R40" ref-type="bibr">40</xref>] and was associated with a fibroblast-like phenotype [<xref rid="R40" ref-type="bibr">40</xref>]. We therefore propose that T/E-induced TGF-&#x003b2; secretion could have autocrine effects promoting tumor progression.</p><fig id="F8" orientation="portrait" position="float"><label>Figure 8</label><caption><title>Working model for T/E-induced effects on BMP/TGF-&#x003b2; and WNT/&#x003b2;-catenin signaling pathways</title><p>T/E VI variant-specific transcriptional modulation of <italic>miR-503</italic> and SMAD7 leads to stronger activation of EMT-regulating genes compared to T/E variant III. Red - upregulation; blue - downregulation.</p></caption><graphic xlink:href="oncotarget-08-25115-g008"/></fig><p>The T/E variants III and VI deploy two routes of ERG-mediated oncogenic pathway activation (Figure <xref ref-type="fig" rid="F8">8</xref>). The first route is characterized by strong upregulation of the TGF-&#x003b2; receptor ALK1, which can be activated by various BMPs, in addition to TGF-&#x003b2;1 and TGF-&#x003b2;3 [<xref rid="R41" ref-type="bibr">41</xref>, <xref rid="R42" ref-type="bibr">42</xref>]. Inhibition of ALK1 in our model led to reduced phosphorylation of p38, downregulation of the EMT-markers <italic>VIM</italic>, <italic>MMP1</italic>, <italic>CDH2</italic>, and <italic>SNAI2</italic>, as well as reduced expression of <italic>ID1</italic> and <italic>ID2</italic>, for which induction by ALK1 signaling is known [<xref rid="R43" ref-type="bibr">43</xref>]. ALK1-induced expression of ID1 promotes tumor cell metastasis [<xref rid="R44" ref-type="bibr">44</xref>]. ID1 was shown to be involved in mesenchymal-to-epithelial transition (MET) of breast cancer cells during lung colonization after having undergone TGF-&#x003b2;-induced EMT [<xref rid="R45" ref-type="bibr">45</xref>]. High levels of ALK1 protein in tumor blood vessels can serve as a prognostic marker for metastatic disease in breast cancer patients [<xref rid="R45" ref-type="bibr">45</xref>]. In addition, the pharmacological inhibition of ALK1 was able to prevent metastatic dissemination and lung colonization in mouse models of endocrine pancreatic and mammary carcinomas [<xref rid="R45" ref-type="bibr">45</xref>, <xref rid="R46" ref-type="bibr">46</xref>]. The high upregulation of ALK1 in T/E expressing cells in our study was accompanied by augmented levels of TGF-&#x003b2;1 and TGF-&#x003b2;2 mRNA and protein, suggesting that autocrine TGF-&#x003b2; signaling mediates ALK1 pathway activation and phenotypic cellular changes in T/E cells [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>].</p><p>The second route of T/E-induced signaling pointed towards FZD4 receptor-mediated WNT/&#x003b2;-catenin signaling as an important element [<xref rid="R49" ref-type="bibr">49</xref>, <xref rid="R50" ref-type="bibr">50</xref>]. Evidence for the role of WNT signaling was seen in the upregulation of transcription factors of the T cell factor/lymphoid enhancer family (<italic>TCF7L2</italic>, <italic>LEF1</italic>), increased &#x003b2;-catenin reporter activity and downregulation of the negative regulator <italic>CDH1</italic> [<xref rid="R51" ref-type="bibr">51</xref>]. These effects were more profound in T/E VI, compared to T/E III, expressing cells. Importantly, <italic>FZD4</italic> was upregulated upon T/E overexpression, and inhibition of FZD4 led to reduced phosphorylation of p38. These results confirmed reports that loss of cell adhesion and EMT were associated with FZD4-induced activation of WNT signaling [<xref rid="R49" ref-type="bibr">49</xref>].</p><p>Our results further suggest that variant-specific transcriptional modulation is responsible for the differences in activation of EMT regulating pathway genes. Strikingly, we observed upregulation of <italic>miR-503</italic> exclusively in T/E VI overexpressing cells. Overexpression of <italic>miR-503</italic> was able to repress expression of SMAD7, a known negative regulator of TGF-&#x003b2; and WNT/&#x003b2;-catenin signaling [<xref rid="R52" ref-type="bibr">52</xref>]. Thus, the <italic>miR-503</italic>-mediated downregulation of <italic>SMAD7</italic> in T/E VI, but not in T/E III cells, explains T/E VI variant-specific transcription. Recently, Li et al. could show that <italic>miR-503</italic> downregulates SMAD7 expression and thereby enhances TGF-&#x003b2; signaling and the metastatic capability of breast cancer cells [<xref rid="R28" ref-type="bibr">28</xref>]. SMAD7-mediated stabilization of &#x003b2;-catenin binding to E-cadherin turned out to increase cell-cell adhesion and formation of adherens junctions [<xref rid="R53" ref-type="bibr">53</xref>], thereby potentially blocking metastasis. Reduced expression of SMAD7 might account for the stronger increase of TGF-&#x003b2; signaling and &#x003b2;-catenin reporter activity observed in T/E VI cells. Zhu et al. showed that stimulation of fibroblasts with recombinant TGF-&#x003b2; results in a decreased expression of SMAD7 [<xref rid="R54" ref-type="bibr">54</xref>]. In agreement with previous reports in MCF-10A breast cancer cells [<xref rid="R55" ref-type="bibr">55</xref>], <italic>TGFB1</italic> knockdown also decreased <italic>miR-503</italic> expression. <italic>MiR-503</italic>-mediated repression of <italic>SMAD7</italic> therefore appears to be a way to escape the inhibitory effect of SMAD7 on TGF-&#x003b2; and WNT/&#x003b2;-catenin signaling. Although <italic>miR-503</italic> expression was shown to be lower in metastatic compared to non-metastatic PCa xenografts [<xref rid="R56" ref-type="bibr">56</xref>], and several studies reported tumor suppressor properties of <italic>miR-503</italic> [<xref rid="R57" ref-type="bibr">57</xref>, <xref rid="R58" ref-type="bibr">58</xref>], in the context of T/E-induced TGF-&#x003b2; signaling <italic>miR-503</italic> overexpression has tumor-promoting effects.</p><p>In conclusion, our study identifies the TGF-&#x003b2;/BMP and WNT/&#x003b2;-catenin signaling pathways as molecular determinants underlying T/E-mediated EMT in PCa cells (Figure <xref ref-type="fig" rid="F8">8</xref>). We confirm that WNT/&#x003b2;-catenin signaling in T/E cells is mediated by FZD4 and propose that <italic>miR-503</italic> plays a crucial role in augmenting this process. We further demonstrate that TGF-&#x003b2;-ALK1-p38 signaling promotes EMT in T/E expressing cells. Our findings suggest that autocrine activation of ALK1 plays a role in PCa cells. This could provide a rational basis for ALK1-blocking agents (which are currently already tested in clinical studies in various malignancies [<xref rid="R59" ref-type="bibr">59</xref>, <xref rid="R60" ref-type="bibr">60</xref>]) to inhibit progression of ERG-positive PCa.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Cell lines and culturing</title><p>LNCaP (CRL-1740) and NCI-H660 (CRL-5813) cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Stably transfected acceptor LNCaP cells were maintained in RPMI1640 (Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% of Tet System Approved FBS (tet-FBS, Clontech, G&#x000f6;teborg, Sweden) and 80 &#x003bc;g/mL hygromycin B (Thermo Fisher Scientific). NCI-H660 cells were maintained in HITES medium supplemented with 5% fetal bovine serum according to the provider's instructions. All cell lines were authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, Germany) as described recently [<xref rid="R61" ref-type="bibr">61</xref>]. The SNP profiles matched known profiles or were unique. The purity of cell lines was validated using the Multiplex cell Contamination Test by Multiplexion (Heidelberg, Germany) as described recently [<xref rid="R62" ref-type="bibr">62</xref>]. No Mycoplasma, SMRV or interspecies contamination was detected.</p></sec><sec id="s4_2"><title>Generation of LNCaP cell models stably expressing T/E variants</title><p>Establishment of the LNCaP-T/E variant cell model including T/E sequences is described in the Supplementary Methods (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1A</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 2</xref>). Transgene expression was induced with 50 ng/mL Dox (Sigma-Aldrich, Munich, Germany) in RPMI1640 containing 10% tet-FBS. Medium of the uninduced cells was supplemented with the respective volume of PBS only.</p></sec><sec id="s4_3"><title>RNA isolation, reverse transcription and quantitative real-time PCR</title><p>Total RNA was isolated from cell lines using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) and quality controlled on the 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany) with RNA 6000 Nano Kit according to manufacturer's protocols. Total RNA was reverse transcribed using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). HotStar<italic>Taq</italic>DNA polymerase (Qiagen) was used for RT-PCR with 50 ng of cDNA template. Relative mRNA levels were assessed by quantitative RT-PCR on the Lightcycler 480 (Roche Diagnostics, Mannheim, Germany) using Universal Probe Library (UPL) assays and primers listed in <xref rid="SD4" ref-type="supplementary-material">Supplementary Table 5</xref>. Linear expression levels were normalized to <italic>GAPDH</italic> using the 2<sup>(&#x02212;&#x00394;&#x00394;Ct)</sup> method [<xref rid="R63" ref-type="bibr">63</xref>]. For miRNA quantification, TaqMan<sup>&#x000ae;</sup> Assays (<italic>hsa-miR-503</italic>, ID: 1048; <italic>RNU6B</italic>, ID: 1093, Thermo Fisher Scientific) were used according to the manufacturer's instruction.</p></sec><sec id="s4_4"><title>Microarray gene expression profiling</title><p>RNA was isolated with the RNase-Free DNase Set (Qiagen) according to the manufacturer's protocol. After quality control, 500 ng of total RNA with a concentration of 50 ng/&#x003bc;l were submitted to the DKFZ Genomics and Proteomics Core Facility (GPCF) for Illumina Whole-Genome Expression Beadchip Analysis (Human HT-12 Chip). The raw data were quantile-normalized using the Bioconductor package <italic>preprocessCore</italic> in R. The microarray data reported in this study are available from the NCBI GEO database (GSE78032). Genes showing expression fold change &#x0003e; 1.5 (<italic>p-value</italic> &#x0003c; 0.05) were considered as differentially expressed and were analyzed with Ingenuity Pathway Analysis (IPA) (see below). Genes involved in relevant biological processes obtained from microarray analysis were validated by qPCR in the same samples that were used for microarray profiling.</p></sec><sec id="s4_5"><title>Luciferase reporter assay</title><p>Cells seeded in triplicate in 96-well plates at 5000 cells/well were treated with Dox and transfected with 100 ng of either wild-type TOPflash or mutant FOPflash reporter plasmid from the TCF Reporter Plasmid Kit (Merck Millipore, Darmstadt, Germany) using the JetPei Polyplus transfection reagent (VWR International, Darmstadt, Germany). Firefly luciferase signals were determined 72 h after transfection using the ONE-Glo<sup>TM</sup> Luciferase Assay System (Promega, Mannheim, Germany). Fold activation of WNT/&#x003b2;-catenin pathway was calculated by dividing wild-type TOPflash by mutant FOPflash activity.</p></sec><sec id="s4_6"><title>siRNA-mediated gene knock-down</title><p>LNCaP-T/E cells were transfected with 20nM siRNA against <italic>TGFB1</italic> (Qiagen) using Lipofectamine RNAiMAX (Thermo Fisher Scientific) and OptiMEM<sup>&#x000ae;</sup> I (Thermo Fisher Scientific) according to the manufacturer's protocol. Cells transfected with nonsilencing AllStars Negative Control siRNA (Qiagen) were used as controls. Cells were treated for 48 h, medium was changed, Dox-supplemented medium was added where indicated and siRNA treatment was repeated. Cells were incubated for 72 h and processed for further analysis.</p><p>NCI-H660 cells were transfected with 50nM siRNA against <italic>ERG</italic> (Qiagen) using Lipofectamine RNAiMAX (Thermo Fisher Scientific) and OptiMEM<sup>&#x000ae;</sup> I (Thermo Fisher Scientific) according to the manufacturer's protocol. Cells transfected with nonsilencing AllStars Negative Control siRNA (Qiagen) were used as controls. Cells were incubated for 72 h and processed for further analysis.</p></sec><sec id="s4_7"><title>miRNA transfection</title><p>For transfection, cells were treated with Dox and transfected with <italic>hsa-miR-503-5p</italic> inhibitor (Exiqon, Vedbaek, Denmark) or <italic>hsa-miR-503-5p</italic> mimic (GE Healthcare, Rosersberg, Sweden) using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific).</p></sec><sec id="s4_8"><title>Pharmacological inhibitors</title><p>The ALK1 inhibitor K02288 (Biomol, Hamburg, Germany) was dissolved at a concentration of 100 mM in DMSO. Further dilutions of K02288 were made in PBS to reduce the final concentration of DMSO in the assay. Equal amounts of DMSO added to the cell culture medium served as negative control. RhALK1 (R&#x00026;D, Wiesbaden, Germany) was dissolved in PBS at a concentration of 100&#x003bc;g/mL, and rhFZD4 (R&#x00026;D) was dissolved in PBS at a concentration of 400 &#x003bc;g/mL. Here, PBS was added to the cell culture medium as a negative control. Inhibitors or control solvents were diluted in Dox-containing tet-FBS medium and added to the cells for 48h.</p></sec><sec id="s4_9"><title>Cell proliferation assay</title><p>Cells were treated with Dox for 48 h and seeded into 96-well plates at 5000 cells/well in 90 &#x003bc;l 10% tet-FBS-containing medium in triplicate. Ten &#x003bc;l of the colorimetric WST-1 reagent (Roche Diagnostics) was added to the medium and incubated at 37&#x000b0;C at the indicated time points. Absorbance was measured one hour after addition of WST-1 reagent using a Tecan Infinite<sup>&#x000ae;</sup> M200 microplate reader (Tecan Group Ltd., M&#x000e4;nnedorf, Switzerland).</p></sec><sec id="s4_10"><title>Migration and invasion assays</title><p><italic>In vitro</italic> cell migration assays were performed in duplicate using 24-well transwell chambers with 8 &#x003bc;m pore size (Merck Millipore). Cells (5 &#x000d7; 10<sup>5</sup> cells/ml) were seeded in the upper chamber in 200 &#x003bc;l serum-free medium. 700 &#x003bc;l of medium supplemented with 10% FBS as chemoattractant was filled into the bottom well. After 48 h of cultivation in 5% CO<sub>2</sub> at 37&#x000b0;C, migrated cells attached to the lower surface of the insert were fixed with 100% methanol on ice and stained with 0.1% Crystal Violet (Sigma- Aldrich). Migrated cells were counted in four random fields under a light microscope (10&#x000d7; magnification).</p><p>Invasion assays were performed analogously after coating the transwell chambers with 100 &#x003bc;l Matrigel (BD Biosciences, Heidelberg, Germany) per filter.</p></sec><sec id="s4_11"><title>Cell cycle analysis</title><p>Twenty-four, 48 and 72 h after Dox induction, trypsinized cells were fixed with 100% ice-cold ethanol and stained with propidium iodide (PI) solution (PBS containing 50 &#x003bc;g/ml PI, 0.1mg/ml RNase A, 0.05% (v/v) Triton X-100). PI staining was analyzed using a FACSCanto II flow cytometer (BD Biosciences). Data was analyzed using the software Cyflogig, version 1.2.1 (CyFlo Ltd., Turku, Finland).</p></sec><sec id="s4_12"><title>Cell lysis and western blot analysis</title><p>Whole-cell lysates were prepared in RIPA lysis buffer (50 mM Tris-HCl pH 8.0, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), supplemented with 1&#x000d7; cOmplete Mini Protease Inhibitor Cocktail (Roche Diagnostics) and 1&#x000d7; PhosSTOP Phosphatase Inhibitor Cocktail (Roche Diagnostics). Lysates were boiled 5 min at 95&#x000b0;C with 4&#x000d7; reducing Roti-Load protein loading buffer (Roth, Karlsruhe, Germany). Samples were separated on a mini polyacrylamide gel (Bio-Rad, Munich, Germany) and transferred to PVDF membranes using the Trans-Blot Turbo semi-dry blotting system (Bio-Rad) at 1.3A, 25V for 7&#x02013;10 min. After blocking with 5% BSA in Tween-20/PBS, membranes were probed with primary antibodies prepared in blocking solution overnight at 4&#x000b0;C on a roller, followed by incubation with horseradish peroxidase-conjugated secondary antibody in blocking solution for 1 h at room temperature and ECL detection (Thermo Fisher Scientific) by the ChemiDoc XRS+ system (Bio-Rad). Western blotting was performed using primary antibodies against ERG (Abcam, Cambridge, UK), and SMAD7 (Abcam), AR (Santa Cruz, Dallas, Texas, USA), p-SMAD1/5, SMAD1, p-p38, p38, p-AKT, AKT, CDH1, and GAPDH (all Cell Signaling Technology, Danvers, MA, USA) at 1:1000 dilution. Secondary antibodies used were anti-rabbit-HRP (at 1:25000 dilution; Dianova, Hamburg, Germany) and anti-mouse-HRP (at 1:10000 dilution; Cell Signaling). Quantitative analysis of protein expression relative to GAPDH was done using Image Lab software (Bio-Rad).</p></sec><sec id="s4_13"><title>Luminex immunoassay</title><p>TGF-&#x003b2; signaling pathway components were analyzed using the Milliplex Human TGF-&#x003b2; signaling 6-plex (Merck Millipore) and the Milliplex Human Multi-pathway 9-plex assay (Merck Millipore). Total TGF-&#x003b2; protein expression in cell lysates and cell culture supernatants were measured using the Milliplex Human TGF-&#x003b2; 1,2,3 assay (Merck Millipore). For Luminex analysis, the cells were treated with Dox to induce ERG expression. For collection, cell lysates and supernatants were centrifuged (15 min, 4000 rpm, 4&#x000b0;C) after 72 h of induction. Immunoassays using Luminex<sup>&#x000ae;</sup> xMAP<sup>&#x000ae;</sup> technology were performed according to the manufacturer's instructions. The fluorescent reporter signals were analyzed by a Bio-Plex 200 reader (Bio-Rad).</p></sec><sec id="s4_14"><title>Ingenuity pathway analysis</title><p>Functional annotation and pathway enrichment of differentially regulated genes were identified using Ingenuity Pathway Analysis (IPA) software (Qiagen). IPA uses the Ingenuity knowledge base, a database of protein and gene interactions integrated from published biomedical literature and 3rd party sources. Analysis using IPA was performed between December 2015 and February 2016 (Ingenuity version 26127183). Genes showing expression fold change &#x0003e; 1.5 were considered as differentially expressed and included in the analysis.</p></sec><sec id="s4_15"><title>Functional annotations</title><p>Gene expression changes were categorized into functional annotations of molecular and cellular mechanisms. The Ingenuity knowledge base provides a predicted direction of change for the biological function (downstream effect analysis), represented by an activation z-score, where z &#x0003e; 2.0 or &#x0003c; &#x02212;2.0 is predictive for activation or reduction of the process, respectively. A <italic>p-value</italic> &#x0003c; 0.05 indicates a statistically significant association between a set of differentially expressed genes and a given process.</p></sec><sec id="s4_16"><title>Pathway enrichment analysis</title><p>Ingenuity knowledge base provides an analysis of metabolic and cell signaling pathways that are significantly enriched in the gene expression signature. Pathway significance values were calculated based on Fisher's right tailed exact test and the &#x02013;log(<italic>p-value</italic>) by IPA. Pathways meeting the threshold <italic>p-value</italic> &#x0003c; 0.05 were considered as significant. Using the &#x02018;Compare&#x02019; tool, IPA identified the intersection and unique gene sets among T/E III and T/E VI versus empty vector datasets. Upstream regulator analysis can identify molecules upstream of the genes in the dataset that potentially explain the observed gene expression changes and molecular functions. It is based on prior knowledge of expected effects between transcriptional regulators and their target genes stored in the Ingenuity knowledge base.</p></sec><sec id="s4_17"><title>Statistical testing</title><p>Expression differences between the induced and uninduced cells were analyzed using a paired <italic>t-test</italic> and between induced cells of T/E III and VI by an unpaired <italic>t-test</italic>. Statistical significance of <italic>t-test</italic> depicted as *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01, ***<italic>p</italic> &#x0003c; 0.001.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY MATERIALS AND METHODS FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-08-25115-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1772" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-25115-s002.xlsx" orientation="portrait" xlink:type="simple" id="d35e1774" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-08-25115-s003.xlsx" orientation="portrait" xlink:type="simple" id="d35e1776" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><media mimetype="application" mime-subtype="docx" xlink:href="oncotarget-08-25115-s004.docx" orientation="portrait" xlink:type="simple" id="d35e1778" position="anchor"/></supplementary-material></sec></body><back><ack><p>We thank Sabrina Gerhardt and Simon Ogrodnik for excellent technical assistance and Jan Mollenhauer for providing access to the LNCaP clones with modified Flp-In system. We thank the DKFZ Genomics and Proteomics Core Facility for performing Illumina Whole-Genome Expression Beadchips and associated statistical analyses.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors declare no competing financial interests.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>This project was supported through intramural funding by the German Cancer Research Center.</p></fn><fn fn-type="con"><p><bold>Authors&#x02019; contributions</bold></p><p>LR, SMK, PA, and HS designed and directed the study. LR, ML, LAK, SMW-B, YT, and SD performed experiments and summarized results. LR and ML analyzed data. LR, PA, SMK, and HS wrote and edited the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>ACPP</term><def><p>Acid phosphatase, prostate</p></def></def-item><def-item><term>AKT</term><def><p>AKT serine/threonine kinase 1</p></def></def-item><def-item><term>ALK1</term><def><p>Activin receptor-like kinase 1</p></def></def-item><def-item><term>AR</term><def><p>Androgen receptor</p></def></def-item><def-item><term>BAMBI</term><def><p>BMP and activin membrane-bound inhibitor</p></def></def-item><def-item><term>BMP</term><def><p>Bone morphogenetic protein</p></def></def-item><def-item><term>CD24</term><def><p>Cluster of differentiation 24</p></def></def-item><def-item><term>CDH1</term><def><p>E-cadherin</p></def></def-item><def-item><term>CDH2</term><def><p>N-cadherin</p></def></def-item><def-item><term>CDK1</term><def><p>Cyclin-dependent kinase 1</p></def></def-item><def-item><term>Dox</term><def><p>Doxycycline</p></def></def-item><def-item><term>EMT</term><def><p>Epithelial-to-mesenchymal transition</p></def></def-item><def-item><term>ERG</term><def><p>V-ets erythroblastosis virus E26 homolog (avian)</p></def></def-item><def-item><term>ERK2</term><def><p>Extracellular signal-regulated kinases, alias of MAPK1</p></def></def-item><def-item><term>Ev</term><def><p>Empty vector</p></def></def-item><def-item><term>FN1</term><def><p>Fibronectin 1</p></def></def-item><def-item><term>FZD4</term><def><p>Frizzled 4</p></def></def-item><def-item><term>GAPDH</term><def><p>Glyceraldehyde-3-phosphate dehydrogenase</p></def></def-item><def-item><term>GO</term><def><p>Gene Ontology</p></def></def-item><def-item><term>ID1 and 2</term><def><p>Inhibitor of differentiation (1 and 2)</p></def></def-item><def-item><term>IPA</term><def><p>Ingenuity Pathway Analysis</p></def></def-item><def-item><term>JNK</term><def><p>c-Jun N-terminal kinases</p></def></def-item><def-item><term>LRP5 and 6</term><def><p>Low-density lipoprotein receptor-related protein 5 and 6</p></def></def-item><def-item><term>MAPK</term><def><p>Mitogen-activated protein kinase</p></def></def-item><def-item><term>MET</term><def><p>Mesenchymal-to-epithelial transition</p></def></def-item><def-item><term>miR</term><def><p>micro-RNA</p></def></def-item><def-item><term>MMP</term><def><p>Matrix metalloproteinase</p></def></def-item><def-item><term>MSMB</term><def><p>Microseminoprotein beta</p></def></def-item><def-item><term>P38</term><def><p>alias of MAPK14, mitogen-activated protein kinase 14</p></def></def-item><def-item><term>pAKT</term><def><p>phospho-AKT</p></def></def-item><def-item><term>PCa</term><def><p>Prostate cancer</p></def></def-item><def-item><term>PI3K</term><def><p>Phosphatidylinositol 3-kinase</p></def></def-item><def-item><term>PLA1A</term><def><p>Phospholipase A1 member A</p></def></def-item><def-item><term>PLAT</term><def><p>Plasminogen activator, tissue type</p></def></def-item><def-item><term>p-p38</term><def><p>phospho-p38</p></def></def-item><def-item><term>pSMAD</term><def><p>phospho-SMAD</p></def></def-item><def-item><term>qPCR</term><def><p>quantitative reverse transcription PCR</p></def></def-item><def-item><term>rhALK1</term><def><p>recombinant decoy receptor ALK1</p></def></def-item><def-item><term>rhFZD4</term><def><p>recombinant decoy receptor FZD4</p></def></def-item><def-item><term>RT-PCR</term><def><p>Reverse transcription PCR</p></def></def-item><def-item><term>siRNA</term><def><p>small interfering RNA</p></def></def-item><def-item><term>SLC45A3</term><def><p>Solute carrier family 45 member 3</p></def></def-item><def-item><term>SMAD</term><def><p>SMAD family protein</p></def></def-item><def-item><term>SNAI2</term><def><p>Snail family transcriptional repressor 2</p></def></def-item><def-item><term>TCF7L2</term><def><p>T cell factor/lymphoid enhancer 2</p></def></def-item><def-item><term>TCF/LEF-1</term><def><p>Transcription factor/lymphoid enhancer binding factor 1</p></def></def-item><def-item><term>TDRD1</term><def><p>Tudor domain containing 1</p></def></def-item><def-item><term>T/E</term><def><p>TMPRSS2:ERG</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p>Transforming growth factor beta</p></def></def-item><def-item><term>TGFB1 and 2</term><def><p>TGF-&#x003b2; 1 and 2</p></def></def-item><def-item><term>TMPRSS2</term><def><p>Transmembrane protease, serine 2</p></def></def-item><def-item><term>VIM</term><def><p>Vimentin</p></def></def-item><def-item><term>VTN</term><def><p>Vitronectin</p></def></def-item><def-item><term>WNT</term><def><p>Wingless-type family member</p></def></def-item><def-item><term>ZEB1</term><def><p>Zinc finger E-box binding homeobox 1</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Steliarova-Foucher</surname><given-names>E</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Rosso</surname><given-names>S</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name><name><surname>Comber</surname><given-names>H</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><fpage>1374</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">23485231</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>XW</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Tchinda</surname><given-names>J</given-names></name><name><surname>Kuefer</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Montie</surname><given-names>JE</given-names></name><name><surname>Shah</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>644</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">16254181</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Bjartell</surname><given-names>A</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name><name><surname>Nam</surname><given-names>RK</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name></person-group><article-title>ETS gene fusions in prostate cancer: from discovery to daily clinical practice</article-title><source>Eur Urol</source><year>2009</year><volume>56</volume><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">19409690</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Laxman</surname><given-names>B</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Helgeson</surname><given-names>BE</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Shah</surname><given-names>RB</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>Role of the TMPRSS2-ERG gene fusion in prostate cancer</article-title><source>Neoplasia</source><year>2008</year><volume>10</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">18283340</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>FH</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Setlur</surname><given-names>S</given-names></name><name><surname>Tchinda</surname><given-names>J</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Hofer</surname><given-names>MD</given-names></name><name><surname>Pienta</surname><given-names>KG</given-names></name><name><surname>Kuefer</surname><given-names>R</given-names></name><name><surname>Vessella</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>XW</given-names></name><etal/></person-group><article-title>TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>8337</fpage><lpage>8341</lpage><pub-id pub-id-type="pmid">16951139</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Dobi</surname><given-names>A</given-names></name><name><surname>Sreenath</surname><given-names>T</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Tadase</surname><given-names>AY</given-names></name><name><surname>Ravindranath</surname><given-names>L</given-names></name><name><surname>Cullen</surname><given-names>J</given-names></name><name><surname>Furusato</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Thangapazham</surname><given-names>RL</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Sesterhenn</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Delineation of TMPRSS2-ERG splice variants in prostate cancer</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>4719</fpage><lpage>4725</lpage><pub-id pub-id-type="pmid">18676740</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linn</surname><given-names>DE</given-names></name><name><surname>Penney</surname><given-names>KL</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>1869</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">26880803</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Merson</surname><given-names>S</given-names></name><name><surname>Jhavar</surname><given-names>S</given-names></name><name><surname>Flohr</surname><given-names>P</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name><name><surname>Eeles</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>FL</given-names></name><name><surname>Phillips</surname><given-names>DH</given-names></name><name><surname>Crundwell</surname><given-names>M</given-names></name><name><surname>Christmas</surname><given-names>T</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><etal/></person-group><article-title>Diversity of TMPRSS2-ERG fusion transcripts in the human prostate</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2667</fpage><lpage>2673</lpage><pub-id pub-id-type="pmid">17043636</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name></person-group><article-title>Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>8347</fpage><lpage>8351</lpage><pub-id pub-id-type="pmid">16951141</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>LJ</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Palanisamy</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Ayala</surname><given-names>G</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name></person-group><article-title>Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>1325</fpage><lpage>1333</lpage><pub-id pub-id-type="pmid">21169414</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Spencer</surname><given-names>DM</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name></person-group><article-title>Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>8516</fpage><lpage>8524</lpage><pub-id pub-id-type="pmid">18922926</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brase</surname><given-names>JC</given-names></name><name><surname>Johannes</surname><given-names>M</given-names></name><name><surname>Mannsperger</surname><given-names>H</given-names></name><name><surname>Falth</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>J</given-names></name><name><surname>Kacprzyk</surname><given-names>LA</given-names></name><name><surname>Andrasiuk</surname><given-names>T</given-names></name><name><surname>Gade</surname><given-names>S</given-names></name><name><surname>Meister</surname><given-names>M</given-names></name><name><surname>Sirma</surname><given-names>H</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Schlomm</surname><given-names>T</given-names></name><etal/></person-group><article-title>TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling</article-title><source>BMC cancer</source><year>2011</year><volume>11</volume><fpage>507</fpage><pub-id pub-id-type="pmid">22142399</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oft</surname><given-names>M</given-names></name><name><surname>Heider</surname><given-names>KH</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name></person-group><article-title>TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis</article-title><source>Curr Biol</source><year>1998</year><volume>8</volume><fpage>1243</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">9822576</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komiya</surname><given-names>Y</given-names></name><name><surname>Habas</surname><given-names>R</given-names></name></person-group><article-title>Wnt signal transduction pathways</article-title><source>Organogenesis</source><year>2008</year><volume>4</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">19279717</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>178</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">24556840</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>KD</given-names></name><name><surname>Setlur</surname><given-names>SR</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Tomlins</surname><given-names>S</given-names></name><name><surname>Tchinda</surname><given-names>J</given-names></name><name><surname>Laxman</surname><given-names>B</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name></person-group><article-title>Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model</article-title><source>Neoplasia</source><year>2007</year><volume>9</volume><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">17401460</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Mani</surname><given-names>RS</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Brenner</surname><given-names>CJ</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Laxman</surname><given-names>B</given-names></name><etal/></person-group><article-title>An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression</article-title><source>Cancer Cell</source><year>2010</year><volume>17</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">20478527</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Dobi</surname><given-names>A</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Thangapazham</surname><given-names>RL</given-names></name><name><surname>Furusato</surname><given-names>B</given-names></name><name><surname>Shaheduzzaman</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Vaidyanathan</surname><given-names>G</given-names></name><name><surname>Whitman</surname><given-names>E</given-names></name><name><surname>Hawksworth</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Nau</surname><given-names>M</given-names></name><etal/></person-group><article-title>TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>5348</fpage><lpage>5353</lpage><pub-id pub-id-type="pmid">18542058</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttice</surname><given-names>G</given-names></name><name><surname>Duterque-Coquillaud</surname><given-names>M</given-names></name><name><surname>Basuyaux</surname><given-names>JP</given-names></name><name><surname>Carrere</surname><given-names>S</given-names></name><name><surname>Kurkinen</surname><given-names>M</given-names></name><name><surname>Stehelin</surname><given-names>D</given-names></name></person-group><article-title>Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex</article-title><source>Oncogene</source><year>1996</year><volume>13</volume><fpage>2297</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">8957070</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moustakas</surname><given-names>A</given-names></name><name><surname>Heldin</surname><given-names>CH</given-names></name></person-group><article-title>Non-Smad TGF-beta signals</article-title><source>J Cell Sci</source><year>2005</year><volume>118</volume><fpage>3573</fpage><lpage>3584</lpage><pub-id pub-id-type="pmid">16105881</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YE</given-names></name></person-group><article-title>Non-Smad pathways in TGF-beta signaling</article-title><source>Cell Res</source><year>2009</year><volume>19</volume><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">19114990</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ao</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Bhowmick</surname><given-names>NA</given-names></name><name><surname>Hayward</surname><given-names>SW</given-names></name></person-group><article-title>Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>8007</fpage><lpage>8016</lpage><pub-id pub-id-type="pmid">16912176</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidle</surname><given-names>UH</given-names></name><name><surname>Schneider</surname><given-names>B</given-names></name><name><surname>Georges</surname><given-names>G</given-names></name><name><surname>Brinkmann</surname><given-names>U</given-names></name></person-group><article-title>Genetically engineered fusion proteins for treatment of cancer</article-title><source>Cancer Genomics Proteomics</source><year>2012</year><volume>9</volume><fpage>357</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">23162075</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanvitale</surname><given-names>CE</given-names></name><name><surname>Kerr</surname><given-names>G</given-names></name><name><surname>Chaikuad</surname><given-names>A</given-names></name><name><surname>Ramel</surname><given-names>MC</given-names></name><name><surname>Mohedas</surname><given-names>AH</given-names></name><name><surname>Reichert</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Triffitt</surname><given-names>JT</given-names></name><name><surname>Cuny</surname><given-names>GD</given-names></name><name><surname>Yu</surname><given-names>PB</given-names></name><name><surname>Hill</surname><given-names>CS</given-names></name><name><surname>Bullock</surname><given-names>AN</given-names></name></person-group><article-title>A new class of small molecule inhibitor of BMP signaling</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e62721</fpage><pub-id pub-id-type="pmid">23646137</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>Miyazawa</surname><given-names>K</given-names></name></person-group><article-title>Id: a target of BMP signaling</article-title><source>Sci STKE</source><year>2002</year><volume>2002</volume><fpage>pe40</fpage><pub-id pub-id-type="pmid">12297674</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiercinska</surname><given-names>E</given-names></name><name><surname>Wickert</surname><given-names>L</given-names></name><name><surname>Denecke</surname><given-names>B</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name><name><surname>Hamzavi</surname><given-names>J</given-names></name><name><surname>Gressner</surname><given-names>AM</given-names></name><name><surname>Thorikay</surname><given-names>M</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Mertens</surname><given-names>PR</given-names></name><name><surname>Breitkopf</surname><given-names>K</given-names></name><name><surname>Dooley</surname><given-names>S</given-names></name></person-group><article-title>Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells</article-title><source>Hepatology</source><year>2006</year><volume>43</volume><fpage>1032</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">16628634</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Ying</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Metastatic heterogeneity of breast cancer cells is associated with expression of a heterogeneous TGFbeta-activating miR424&#x02013;503 gene cluster</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>6107</fpage><lpage>6118</lpage><pub-id pub-id-type="pmid">25164015</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butz</surname><given-names>H</given-names></name><name><surname>Racz</surname><given-names>K</given-names></name><name><surname>Hunyady</surname><given-names>L</given-names></name><name><surname>Patocs</surname><given-names>A</given-names></name></person-group><article-title>Crosstalk between TGF-beta signaling and the microRNA machinery</article-title><source>Trends Pharmacol Sci</source><year>2012</year><volume>33</volume><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">22613783</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leshem</surname><given-names>O</given-names></name><name><surname>Madar</surname><given-names>S</given-names></name><name><surname>Kogan-Sakin</surname><given-names>I</given-names></name><name><surname>Kamer</surname><given-names>I</given-names></name><name><surname>Goldstein</surname><given-names>I</given-names></name><name><surname>Brosh</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>Y</given-names></name><name><surname>Jacob-Hirsch</surname><given-names>J</given-names></name><name><surname>Ehrlich</surname><given-names>M</given-names></name><name><surname>Ben-Sasson</surname><given-names>S</given-names></name><name><surname>Goldfinger</surname><given-names>N</given-names></name><name><surname>Loewenthal</surname><given-names>R</given-names></name><name><surname>Gazit</surname><given-names>E</given-names></name><etal/></person-group><article-title>TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e21650</fpage><pub-id pub-id-type="pmid">21747944</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>SH</given-names></name><name><surname>Hyde</surname><given-names>C</given-names></name><name><surname>Reid</surname><given-names>IN</given-names></name><name><surname>Hitchcock</surname><given-names>IS</given-names></name><name><surname>Hart</surname><given-names>CA</given-names></name><name><surname>Bryden</surname><given-names>AA</given-names></name><name><surname>Villette</surname><given-names>JM</given-names></name><name><surname>Stower</surname><given-names>MJ</given-names></name><name><surname>Maitland</surname><given-names>NJ</given-names></name></person-group><article-title>Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma</article-title><source>Prostate</source><year>2002</year><volume>52</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">12210485</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation</article-title><source>Anticancer Res</source><year>2008</year><volume>28</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">18383865</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker-Santos</surname><given-names>DD</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Ghaffari</surname><given-names>M</given-names></name><name><surname>Vickers</surname><given-names>ED</given-names></name><name><surname>Lehman</surname><given-names>M</given-names></name><name><surname>Altamirano-Dimas</surname><given-names>M</given-names></name><name><surname>Oloumi</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dedhar</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>ME</given-names></name></person-group><article-title>Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models</article-title><source>Carcinogenesis</source><year>2012</year><volume>33</volume><fpage>2558</fpage><lpage>2567</lpage><pub-id pub-id-type="pmid">23027626</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Helfand</surname><given-names>BT</given-names></name><name><surname>Jang</surname><given-names>TL</given-names></name><name><surname>Zhu</surname><given-names>LJ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Kozlowski</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Kundu</surname><given-names>SD</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Raji</surname><given-names>AA</given-names></name><name><surname>Javonovic</surname><given-names>B</given-names></name><name><surname>Pins</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>3557</fpage><lpage>3567</lpage><pub-id pub-id-type="pmid">19447876</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>P</given-names></name><name><surname>Polikowsky</surname><given-names>H</given-names></name><name><surname>Pickup</surname><given-names>MW</given-names></name><name><surname>Gorska</surname><given-names>AE</given-names></name><name><surname>Jovanovic</surname><given-names>B</given-names></name><name><surname>Shaw</surname><given-names>AK</given-names></name><name><surname>Novitskiy</surname><given-names>SV</given-names></name><name><surname>Hong</surname><given-names>CC</given-names></name><name><surname>Moses</surname><given-names>HL</given-names></name></person-group><article-title>Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e67533</fpage><pub-id pub-id-type="pmid">23840733</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Pham</surname><given-names>LK</given-names></name><name><surname>Liao</surname><given-names>CP</given-names></name><name><surname>Frenkel</surname><given-names>B</given-names></name><name><surname>Reddi</surname><given-names>AH</given-names></name><name><surname>Roy-Burman</surname><given-names>P</given-names></name></person-group><article-title>A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">18172312</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bubendorf</surname><given-names>L</given-names></name><name><surname>Schopfer</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Willi</surname><given-names>N</given-names></name><name><surname>Gasser</surname><given-names>TC</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name></person-group><article-title>Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients</article-title><source>Hum Pathol</source><year>2000</year><volume>31</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">10836297</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wikstrom</surname><given-names>P</given-names></name><name><surname>Stattin</surname><given-names>P</given-names></name><name><surname>Franck-Lissbrant</surname><given-names>I</given-names></name><name><surname>Damber</surname><given-names>JE</given-names></name><name><surname>Bergh</surname><given-names>A</given-names></name></person-group><article-title>Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer</article-title><source>Prostate</source><year>1998</year><volume>37</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">9721065</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shariat</surname><given-names>SF</given-names></name><name><surname>Shalev</surname><given-names>M</given-names></name><name><surname>Menesses-Diaz</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>IY</given-names></name><name><surname>Kattan</surname><given-names>MW</given-names></name><name><surname>Wheeler</surname><given-names>TM</given-names></name><name><surname>Slawin</surname><given-names>KM</given-names></name></person-group><article-title>Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>2856</fpage><lpage>2864</lpage><pub-id pub-id-type="pmid">11387358</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><name><surname>Ericson</surname><given-names>N</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Lam</surname><given-names>HM</given-names></name><name><surname>Brown</surname><given-names>LG</given-names></name><name><surname>Ketchanji</surname><given-names>M</given-names></name><name><surname>Nghiem</surname><given-names>B</given-names></name><name><surname>Lakely</surname><given-names>B</given-names></name><name><surname>Coleman</surname><given-names>R</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Lange</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases</article-title><source>Clin Exp Metastasis</source><year>2016</year><volume>33</volume><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">26667932</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goumans</surname><given-names>MJ</given-names></name><name><surname>Valdimarsdottir</surname><given-names>G</given-names></name><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Rosendahl</surname><given-names>A</given-names></name><name><surname>Sideras</surname><given-names>P</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name></person-group><article-title>Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><fpage>1743</fpage><lpage>1753</lpage><pub-id pub-id-type="pmid">11927558</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>L</given-names></name><name><surname>Mallet</surname><given-names>C</given-names></name><name><surname>Mazerbourg</surname><given-names>S</given-names></name><name><surname>Feige</surname><given-names>JJ</given-names></name><name><surname>Bailly</surname><given-names>S</given-names></name></person-group><article-title>Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>1953</fpage><lpage>1961</lpage><pub-id pub-id-type="pmid">17068149</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Sugizaki</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Miyazawa</surname><given-names>K</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><article-title>Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells</article-title><source>J Cell Physiol</source><year>2002</year><volume>193</volume><fpage>299</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">12384983</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stankic</surname><given-names>M</given-names></name><name><surname>Pavlovic</surname><given-names>S</given-names></name><name><surname>Chin</surname><given-names>Y</given-names></name><name><surname>Brogi</surname><given-names>E</given-names></name><name><surname>Padua</surname><given-names>D</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name><name><surname>Benezra</surname><given-names>R</given-names></name></person-group><article-title>TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition</article-title><source>Cell Rep</source><year>2013</year><volume>5</volume><fpage>1228</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">24332369</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>SI</given-names></name><name><surname>Bocci</surname><given-names>M</given-names></name><name><surname>Lovrot</surname><given-names>J</given-names></name><name><surname>Eleftheriou</surname><given-names>N</given-names></name><name><surname>Roswall</surname><given-names>P</given-names></name><name><surname>Cordero</surname><given-names>E</given-names></name><name><surname>Lindstrom</surname><given-names>L</given-names></name><name><surname>Bartoschek</surname><given-names>M</given-names></name><name><surname>Haller</surname><given-names>BK</given-names></name><name><surname>Pearsall</surname><given-names>RS</given-names></name><name><surname>Mulivor</surname><given-names>AW</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>2445</fpage><lpage>2456</lpage><pub-id pub-id-type="pmid">26077471</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>D</given-names></name><name><surname>Pobre</surname><given-names>EG</given-names></name><name><surname>Mulivor</surname><given-names>AW</given-names></name><name><surname>Grinberg</surname><given-names>AV</given-names></name><name><surname>Castonguay</surname><given-names>R</given-names></name><name><surname>Monnell</surname><given-names>TE</given-names></name><name><surname>Solban</surname><given-names>N</given-names></name><name><surname>Ucran</surname><given-names>JA</given-names></name><name><surname>Pearsall</surname><given-names>RS</given-names></name><name><surname>Underwood</surname><given-names>KW</given-names></name><name><surname>Seehra</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group><article-title>ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth</article-title><source>Mol Cancer Ther</source><year>2010</year><volume>9</volume><fpage>379</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">20124460</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Obberghen-Schilling</surname><given-names>E</given-names></name><name><surname>Roche</surname><given-names>NS</given-names></name><name><surname>Flanders</surname><given-names>KC</given-names></name><name><surname>Sporn</surname><given-names>MB</given-names></name><name><surname>Roberts</surname><given-names>AB</given-names></name></person-group><article-title>Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells</article-title><source>J Biol Chem</source><year>1988</year><volume>263</volume><fpage>7741</fpage><lpage>7746</lpage><pub-id pub-id-type="pmid">3259578</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name></person-group><article-title>TGF-beta and epithelial-to-mesenchymal transitions</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>5764</fpage><lpage>5774</lpage><pub-id pub-id-type="pmid">16123809</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Iljin</surname><given-names>K</given-names></name><name><surname>Sara</surname><given-names>H</given-names></name><name><surname>Mpindi</surname><given-names>JP</given-names></name><name><surname>Mirtti</surname><given-names>T</given-names></name><name><surname>Vainio</surname><given-names>P</given-names></name><name><surname>Rantala</surname><given-names>J</given-names></name><name><surname>Alanen</surname><given-names>K</given-names></name><name><surname>Nees</surname><given-names>M</given-names></name><name><surname>Kallioniemi</surname><given-names>O</given-names></name></person-group><article-title>FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>6735</fpage><lpage>6745</lpage><pub-id pub-id-type="pmid">20713528</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>JC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>6068</fpage><lpage>6079</lpage><pub-id pub-id-type="pmid">23913826</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herzig</surname><given-names>M</given-names></name><name><surname>Savarese</surname><given-names>F</given-names></name><name><surname>Novatchkova</surname><given-names>M</given-names></name><name><surname>Semb</surname><given-names>H</given-names></name><name><surname>Christofori</surname><given-names>G</given-names></name></person-group><article-title>Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2290</fpage><lpage>2298</lpage><pub-id pub-id-type="pmid">17043652</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavsak</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>RK</given-names></name><name><surname>Causing</surname><given-names>CG</given-names></name><name><surname>Bonni</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Thomsen</surname><given-names>GH</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name></person-group><article-title>Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation</article-title><source>Mol Cell</source><year>2000</year><volume>6</volume><fpage>1365</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">11163210</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Clemens</surname><given-names>TL</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title>Smad7 stabilizes beta-catenin binding to E-cadherin complex and promotes cell-cell adhesion</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>23956</fpage><lpage>23963</lpage><pub-id pub-id-type="pmid">18593713</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>You</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Zuo</surname><given-names>X</given-names></name></person-group><article-title>MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma</article-title><source>J Clin Immunol</source><year>2012</year><volume>32</volume><fpage>514</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">22307526</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llobet-Navas</surname><given-names>D</given-names></name><name><surname>Rodriguez-Barrueco</surname><given-names>R</given-names></name><name><surname>Castro</surname><given-names>V</given-names></name><name><surname>Ugalde</surname><given-names>AP</given-names></name><name><surname>Sumazin</surname><given-names>P</given-names></name><name><surname>Jacob-Sendler</surname><given-names>D</given-names></name><name><surname>Demircan</surname><given-names>B</given-names></name><name><surname>Castillo-Martin</surname><given-names>M</given-names></name><name><surname>Putcha</surname><given-names>P</given-names></name><name><surname>Marshall</surname><given-names>N</given-names></name><name><surname>Villagrasa</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>F</given-names></name><etal/></person-group><article-title>The miR-424 (322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland</article-title><source>Genes Dev</source><year>2014</year><volume>28</volume><fpage>765</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">24636986</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watahiki</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Dennis</surname><given-names>K</given-names></name><name><surname>O&#x02018;Dwyer</surname><given-names>HM</given-names></name><name><surname>Gleave</surname><given-names>M</given-names></name><name><surname>Gout</surname><given-names>PW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNAs associated with metastatic prostate cancer</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e24950</fpage><pub-id pub-id-type="pmid">21980368</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oneyama</surname><given-names>C</given-names></name><name><surname>Kito</surname><given-names>Y</given-names></name><name><surname>Asai</surname><given-names>R</given-names></name><name><surname>Ikeda</surname><given-names>J</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Okuzaki</surname><given-names>D</given-names></name><name><surname>Kokuda</surname><given-names>R</given-names></name><name><surname>Kakumoto</surname><given-names>K</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Morii</surname><given-names>E</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name></person-group><article-title>MiR-424/503-mediated Rictor upregulation promotes tumor progression</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e80300</fpage><pub-id pub-id-type="pmid">24244675</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>GATA3-driven expression of miR-503 inhibits prostate cancer progression by repressing ZNF217 expression</article-title><source>Cell Signal</source><year>2016</year><volume>28</volume><fpage>1216</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">27267060</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vecchia</surname><given-names>L</given-names></name><name><surname>Olivieri</surname><given-names>C</given-names></name><name><surname>Scotti</surname><given-names>C</given-names></name></person-group><article-title>Activin Receptor-like kinase 1: a novel anti-angiogenesis target from TGF-beta family</article-title><source>Mini Rev Med Chem</source><year>2013</year><volume>13</volume><fpage>1398</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">23815578</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>Gordon</surname><given-names>MS</given-names></name><name><surname>Hurwitz</surname><given-names>HI</given-names></name><name><surname>Jones</surname><given-names>SF</given-names></name><name><surname>Mendelson</surname><given-names>DS</given-names></name><name><surname>Blobe</surname><given-names>GC</given-names></name><name><surname>Agarwal</surname><given-names>N</given-names></name><name><surname>Condon</surname><given-names>CH</given-names></name><name><surname>Wilson</surname><given-names>D</given-names></name><name><surname>Pearsall</surname><given-names>AE</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>McClure</surname><given-names>T</given-names></name><name><surname>Attie</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>480</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">24173543</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>F</given-names></name><name><surname>Dirks</surname><given-names>WG</given-names></name><name><surname>Fahnrich</surname><given-names>S</given-names></name><name><surname>Hotz-Wagenblatt</surname><given-names>A</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name></person-group><article-title>High-throughput SNP-based authentication of human cell lines</article-title><source>Int J Cancer</source><year>2013</year><volume>132</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">22700458</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><article-title>High-throughput detection and multiplex identification of cell contaminations</article-title><source>Nucleic Acids Res</source><year>2009</year><volume>37</volume><fpage>e119</fpage><pub-id pub-id-type="pmid">19589807</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaffl</surname><given-names>MW</given-names></name></person-group><article-title>A new mathematical model for relative quantification in real-time RT-PCR</article-title><source>Nucleic Acids Res</source><year>2001</year><volume>29</volume><fpage>e45</fpage><pub-id pub-id-type="pmid">11328886</pub-id></element-citation></ref></ref-list></back></article>